Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin.
AIM: Nonvalvular atrial fibrillation (NVAF) requires long-term anticoagulation treatment, which may necessitate frequent primary care visits. MATERIALS & METHODS: NVAF patients initiating warfarin or apixaban in 2012-2017 were identified from linked primary (Clinical Practice Research Datalink) and secondary care (Hospital Episode Statistics) data. A propensity score matched Cox regression model compared discontinuation risk. Primary care visits were compared via negative binomial regression.
RESULTS: A total of 2695 apixaban users were matched to warfarin patients. Discontinuation risk was lower with apixaban than warfarin (hazard ratio: 0.40; 95% CI: 0.35-0.46). Apixaban patients averaged 12.2 annual primary care visits, versus 17.1 for warfarin users (p < 0.001).
CONCLUSION: Apixaban was associated with reduced rates of discontinuation and primary care visits compared with warfarin.
|ジャーナル名||Journal of comparative effectiveness research|
|投稿者||Ramagopalan, Sreeram V; Graham, Sophie; Carroll, Robert; Raluy-Callado, Mireia; Nordstrom, Beth L; Donaldson, Robert; Colby, Chris; Mehmud, Faisal; Alikhan, Raza|
|組織名||Centre for Observational Research & Data Sciences, Bristol-Myers Squibb,;Uxbridge, UB8 1DH, UK.;Evidera, Real-World Evidence, London, W6 8DL, UK.;Evidera, Real-World Evidence, Waltham, MA 02541, USA.;Evidera, Real-World Evidence, San Francisco, CA 94111, USA.;Bristol-Myers Squibb, Uxbridge, UB8 1DH, UK.;Department of Haematology, University Hospital of Wales, Cardiff, CF14 4XW, UK.|